New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 1, 2013
09:25 EDTDELL, ALKS, LTM, MAT, MCK, NFLX, VVUS, GDOT, CTRP, TSN, MRK, ADNC, ELNOn The Fly: Pre-market Movers
UP AFTER EARNINGS/GUIDANCE: Audience (ADNC), up 30%... Tyson Foods (TSN), up 3.3%... Ctrip.com (CTRP), up 8.5%... Green Dot (GDOT), up 6.5%... ALSO HIGHER: Dell (DELL), up 6% after Reuters says 'go private' deal may happen Monday... VIVUS (VVUS), up 5.7% after study published on weight loss drug improving cardiovascular disease risk factors... Netflix (NFLX), up 3.3% after Morgan Stanley raises price target on shares to $200... DOWN AFTER EARNINGS/GUIDANCE: Merck (MRK), down 2.9%... McKesson (MCK), down 2.1%... Mattel (MAT), down 1.7%... Life Time Fitness (LTM), down 16.4%... ALSO LOWER: Alkermes (ALKS), down 5.9% after Elan (ELN) to sell remaining stake, shares downgraded to Neutral at BofA Merrill Lynch.
News For DELL;ADNC;MRK;TSN;CTRP;GDOT;VVUS;NFLX;MCK;MAT;LTM;ALKS;ELN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
September 19, 2014
05:18 EDTNFLXNetflix now available in France, Germany, four other European countries
Subscribe for More Information
September 18, 2014
16:27 EDTVVUSOn The Fly: Closing Wrap
Subscribe for More Information
16:00 EDTNFLXOptions Update; September 18, 2014
Subscribe for More Information
14:09 EDTVVUSVIVUS rallies, mean-reverting to intraday trend line
The shares have traded in an extremely wide range today on nearly 20 times daily average volume. An intraday trend line appears currently to be broken. That line is at $4.60 now, and projecting forward would be at the $4.80 area by the close. At the current price of $4.50, support is at $4.41 and then at $4.32.
12:45 EDTVVUSOn The Fly: Midday Wrap
Subscribe for More Information
11:55 EDTMCKRite Aid falls as drugstore chain trims FY15 view
Subscribe for More Information
09:36 EDTVVUSActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL YHOO TWTR VVUS RAD PWE WFM TSLA PIR SHLD
09:32 EDTNFLXNetflix domestic estimates raised at ITG Research
ITG raised Netflix's domestic estimates given an acceleration in August. The firm's data indicates a faster than expected improvement in ASP and improved churn trends. The analyst raised its Q3 domestic streaming revenue of $881.3M from $877.3M, above guidance of $877M and consensus of $876.3M.
09:02 EDTMCKRite Aid sees current competitive enviornment to remain promotional in FY15
Subscribe for More Information
08:59 EDTVVUSOn The Fly: Pre-market Movers
Subscribe for More Information
08:48 EDTMRKNeogen's dairy genomic program to be marketed by Merck
Subscribe for More Information
06:12 EDTGDOTGreen Dot to acquire Santa Barbara Tax Products Group for $320M
Subscribe for More Information
06:08 EDTGDOTGreen Dot expects to launch 'major new program' to make positive 2014 impact
Subscribe for More Information
06:06 EDTGDOTGreen Dot cuts FY14 adjusted EBITDA to $122M-$126M from $128M-$132M
Subscribe for More Information
06:05 EDTGDOTGreen Dot cuts FY14 non-GAAP revenue to $610M-$620M from $640M-$650M
Subscribe for More Information
06:05 EDTVVUSVIVUS, Auxilium announce FDA approval of STENDRA sNDA
VIVUS (VVUS) and Auxilium Pharmaceuticals (AUXL) announced that the FDA has approved a supplemental new drug application, or sNDA, for STENDRA. STENDRA is now the only FDA-approved erectile dysfunction, or ED, medication indicated to be taken as early as approximately 15 minutes before sexual activity. STENDRA is a prescription medication in a class of drugs known as phosphodiesterase type 5, or PDE5, inhibitors approved for the treatment of ED in men 18 years or older. STENDRA is available in multiple dosage strengths and may be taken with or without food and moderate alcohol consumption. In clinical studies, when compared to placebo, STENDRA helped more men achieve an erection in as early as approximately 15 minutes that lasted long enough to successfully complete sexual intercourse.
06:04 EDTGDOTGreen Dot cuts FY14 non-GAAP EPS $1.25-$1.29 from $1.37-$1.41, consensus $1.42
Subscribe for More Information
06:00 EDTNFLXNetflix implied volatility of 26 at lower end of index mean range
Subscribe for More Information
September 17, 2014
09:33 EDTMRKMerck announced positive results from Phase 3 data for omarigliptin
Subscribe for More Information
08:31 EDTMRKMerck, Sun Pharma enter into licensing agreement for Tildrakizumab
Merck and Sun Pharmaceutical Industries, through their respective subsidiaries,announced an exclusive worldwide licensing agreement for Merck’s investigational therapeutic antibody candidate, tildrakizumab, which is currently being evaluated in Phase 3 registration trials for the treatment of chronic plaque psoriasis, a skin ailment. Under terms of the agreement, Sun Pharma will acquire worldwide rights to tildrakizumab for use in all human indications from Merck in exchange for an upfront payment of $80M. Merck will continue all clinical development and regulatory activities, which will be funded by Sun Pharma. Upon product approval, Sun Pharma will be responsible for regulatory activities, including subsequent submissions, pharmacovigilance, post approval studies, manufacturing and commercialization of the approved product. Merck is eligible to receive undisclosed payments associated with regulatory and sales milestones, as well as tiered royalties ranging from mid-single digit through teen percentage rates on sales. The transaction is subject to customary closing conditions, including the requirements under the Hart Scott-Rodino Antitrust Improvements Act.
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use